SBSimone Braig

Simone Braig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simone Braig has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Angelika M. Vollmar

    Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich (LMU), Butenandtstrasse 5-13, Munich, D-81377, Germany

    2 shared publications
  • Olga Nagło

    Department of Pharmaceutical Biology, Ludwig Maximilian University of Munich

    2 shared publications
  • Stefan Zahler

    Department of Pharmaceutical Biology, Ludwig Maximilian University of Munich

    2 shared publications
  • Andreas Koeberle

    Michael Popp Institute and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria

    1 shared publication
  • Behnaz A. Abhari

    Institute for Experimental Cancer Research in Pediatrics, J.W. Goethe University Hospital Frankfurt, Frankfurt a. M., Germany

    1 shared publication
  • Binje Vick

    Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany

    1 shared publication

Latest Publications

  • Open Access

    Neocarzilin A Is a Potent Inhibitor of Cancer Cell Motility Targeting VAT-1 Controlled Pathways

    by Carolin M.-L. Gleissner, Carolin L. Pyka, Wolfgang Heydenreuter, Thomas F. Gronauer, Carina Atzberger, Vadim S. Korotkov, Weiting Cheng, Stephan M. Hacker, Angelika M. Vollmar, Simone Braig, et al.

    The natural product neocarzilin A (NCA) was discovered decades ago, and despite its potent cytotoxic effects no mode of action studies have been performed up to date. Synthesis of neocarzilins A, B, and C and a stereoisomer of NCA provided insights into structural preferences as well as access to probes for functional studies. NCA turned out to be the most active member and was not only effective against cell proliferation but also migration, a novel and so far overlooked activity. To decipher the molecular mode of action, we applied chemical proteomics for target discovery and revealed that NCA targets cancer cell migration via irreversible binding to the largely uncharacterized synaptic vesicle membrane protein VAT-1. A corresponding knockout of the protein confirmed the phenotype, and pull-down studies showed the interaction with an intricate network of key migration mediators such as Talin-1. Overall, we introduce VAT-1 as a promising novel target for the development of selective migration inhibitors with the perspective to limit toxicity in the absence of antiproliferative effects.


  • Open Access

    Targeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics

    by Fabian Koczian, Olga Nagło, Jan Vomacka, Binje Vick, Phil Servatius, Themistoklis Zisis, Britta Hettich, Uli Kazmaier, Stephan A. Sieber, Irmela Jeremias, et al.

    Combination chemotherapy has proved to be a favorable strategy to treat acute leukemia. However, the introduction of novel compounds remains challenging and is hindered by a lack of understanding their mechanistic interaction with established drugs. In the present study, we demonstrate a highly increased response of various acute leukemia cell lines, drug resistant cells and patient-derived xenograft cells by combining the recently introduced protein disulfide isomerase inhibitor PS89 with cytostatics. In leukemic cells, a proteomics based target fishing approach disclosed that PS89 impacts a whole network of endoplasmic reticulum homeostasis proteins. We elucidate that the strong apoptosis induction in combination with cytostatics is orchestrated by the PS89 target B-cell receptor-associated protein 31, which transduces apoptosis signals at the ER-mitochondria interface. Activation of caspase-8 and cleavage of BAP31 stimulate a pro-apoptotic crosstalk including endoplasmic reticulum calcium release and increased reactive oxygen species levels resulting in amplification of mitochondrial apoptosis. This study promotes PS89 as a novel chemosensitizing agent for acute leukemia treatment and uncovers that targeting the endoplasmic reticulum-mitochondria network of cell death is a promising approach in combination therapy.


  • Open Access

    Targeting de novo lipogenesis as a novel approach in anti-cancer therapy

    by Katharina Stoiber, Olga Nagło, Carla Pernpeintner, Siwei Zhang, Andreas Koeberle, Melanie Ulrich, Oliver Werz, Rolf Müller, Stefan Zahler, Theobald Lohmüller, et al.

    Although altered membrane physiology has been discussed within the context of cancer, targeting membrane characteristics by drugs being an attractive therapeutic strategy has received little attention so far. Various acetyl-CoA carboxylase 1 (ACC1), and fatty acid synthase (FASN) inhibitors (like Soraphen A and Cerulenin) as well as genetic knockdown approaches were employed to study the effects of disturbed phospholipid composition on membrane properties and its functional impact on cancer progression. By using state-of-the-art methodologies such as LC-MS/MS, optical tweezers measurements of giant plasma membrane vesicles and fluorescence recovery after photobleaching analysis, membrane characteristics were examined. Confocal laser scanning microscopy, proximity ligation assays, immunoblotting as well as migration, invasion and proliferation experiments unravelled the functional relevance of membrane properties in vitro and in vivo. By disturbing the deformability and lateral fluidity of cellular membranes, the dimerisation, localisation and recycling of cancer-relevant transmembrane receptors is compromised. Consequently, impaired activation of growth factor receptor signalling cascades results in abrogated tumour growth and metastasis in different in vitro and in vivo models. This study highlights the field of membrane properties as a promising druggable cellular target representing an innovative strategy for development of anti-cancer agents.


  • The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer

    by Simone Braig, Fabian Bischoff, Behnaz A. Abhari, Laurent Meijer, Simone Fulda, Leandros Skaltsounis, Angelika M. Vollmar